Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases

Journal of Clinical Oncology

Volumn 15, Issue 6, 1997, Pages 2359-2370

  Berd, David ^a   Maguire Jr , Henry C ^a   Schuchter, Lynn M ^a   Hamilton, Ralph ^a   Hauck, Walter W ^a   Sato, Takami ^a   Mastrangelo, Michael J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DINITROPHENOL; BCG VACCINE; CYCLOPHOSPHAMIDE; MELANOMA VACCINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DELAYED HYPERSENSITIVITY; FEMALE; FOLLOW UP; HUMAN; INTRADERMAL DRUG ADMINISTRATION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; VACCINE PRODUCTION;

EID: 0030986643     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.6.2359     Document Type: Article

References (34)

1. Balch CM, Soong S-J, Murad TM, et al: A multifactorial analysis of melanoma. III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 193:377-388, 1981
2. Coit DG, Rogatko A, Brennan MF: Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes: A multivariate analysis. Ann Surg 214:627-636, 1991
3. Karakousis CP, Seddiq MK, Moore R: Prognostic value of lymph node dissection in malignant melanoma. Arch Surg 115:719-722, 1980
4. Slingluff CL Jr, Stidham KR, Ricci WM, et al: Surgical management of regional lymph nodes in patients with melanoma: Experience with 4682 patients. Ann Surg 219:120-130, 1994
5. Retsas S, Quigley M, Pectasides D, et al: Clinical and histologic involvement of regional lymph nodes in malignant melanoma: Adjuvant vindesine improves survival. Cancer 73:2119-2130, 1994
6. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 14:7-17, 1996
7. Berd D, Murphy G, Maguire HC Jr, et al: Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. Cancer Res 51:2731-2734, 1991
8. Sato T, McCue P, Masuoka K, et al: Interleukin 10 production by human melanoma. Clin Cancer Res 2:1383-1390, 1996
9. Berd D, Maguire HC Jr, Mastrangelo MJ: Treatment of human melanoma with a hapten-modified autologous vaccine. Ann NY Acad Sci 690:147-152, 1993
10. Berd D, Maguire HC Jr, Mastrangelo MJ: Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46:2572-2577, 1986
11. Miller SD, Claman HN: The induction of hapten-specific T cell tolerance by using hapten-modified lymphoid cells. I. Characteristics of tolerance induction. J Immunol 117:1519-1526, 1976
12. Berd D, Mastrangelo MJ, Engstrom PF, et al: Augmentation of the human immune response by cyclophosphamide. Cancer Res 42:4862-4866, 1982
13. Berd D, Mastrangelo MJ: Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. Cancer Invest 6:337-349, 1988
14. Gadd MA, Coit DG: Recurrence patterns and outcome in 1019 patients undergoing axillary or inguinal lymphadenectomy for melanoma. Arch Surg 127:1412-1416, 1992
15. Mitchell MS: Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J Clin Oncol 7:1701-1709, 1989
16. McClay EF, Mastrangelo MJ, Bellet RE, et al: Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 71:465-469, 1987
17. Berd D, Maguire HC Jr, Mastrangelo MJ, et al: Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine. Cancer Immunol Immunother 39:141-147, 1994
18. Maguire HC Jr, Ettore VL: Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig. J Invest Dermatol 48:39-42, 1967
19. Murphy GF, Radu A, Kaminer M, et al: Autologous melanoma vaccine induces inflammatory responses in melanoma metastases: Relevance to immunologic regression and immunotherapy. J Invest Dermatol 100:3355-3418, 1993
20. Lattime EC, Mastrangelo MJ, Bagasra O, et al: Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol Immunother 41:151-156, 1995
21. Sensi M, Farina C, Maccalli C, et al: Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine. J Clin Invest 99:710-717, 1997
22. Shearer GM: Cell-mediated cytotoxicity to trinitrophenyl-modified syngeneic lymphocytes. Eur J Immunol 4:527-533, 1974
23. Neurath MF, Fuss I, Kelsall BL, et al: Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182:1281-1290, 1995
24. Tsutsui H, Terano Y, Sakagami C, et al: Drug-specific T cells derived from patients with drug-induced allergic hepatitis. J Immunol 149:706-716, 1992
25. de Week AL: Pharmacologic and immunochemical mechanisms of drug hypersensitivity. Immunol Allerg Clin North Am 11:461-474, 1991
26. Gilliland BC: Drug-induced autoimmune and hematologic disorders. Immunol Allerg Clin North Am 11:525-553, 1991
27. Ortmann B, Martin S, Von Bonin A, et al: Synthetic peptides anchor T cell-specific TNP epitopes to MHC antigens. J Immunol 148:1445-1450, 1992
28. b-restricted TNP epitopes. J Immunol 151:678-687, 1993
29. Kim BS, Jang YS: Constraints in antigen processing result in unresponsiveness to a T cell epitope of hen egg lysozyme in C57BL/ 6 mice. Eur J Immunol 22:775-782, 1992
30. Weksler ME, Schwab R, Huetz F, et al: Cellular basis for the age-associated increase in autoimmune reactions. Int Immunol 2:329-335, 1990
31. Kalm O, Johnson U, Prellner K, et al: HLA frequency in patients with recurrent acute otitis media. Arch Otolaryngol Head Neck Surg 117:1296-1299, 1991
32. Giardiello FM, Lazenby AJ, Yardley JH, et al: Increased HLA A1 and diminished HLA A3 in lymphocytic colitis compared to controls and patients with collagenous colitis. Dig Dis Sci 37:496-499, 1992
33. Livingston PO, Wong GYC, Adluri S, et al: Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036-1044, 1994
34. Wallack MK, Sivanandham M, Balch CM, et al: A phase III randomized, double-blind, multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 75:34-42, 1995